Listing of BerGenBio ASA at Oslo Børs

Markets, Stock Markets — By on April 7, 2017 at 8:11 AM

Applied date:28/03/2017

Accepted date:31/03/2017

Listing date:07/04/2017


BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drugs for most aggressive cancers. Ongoing international clinical trials with the Company’s lead product BGB324 is in patients with lung cancer and leukaemia. The Company is a world leader in understanding the central role of AXL kinase in driving immune evasion, drug resistance and metastasis, key traits of aggressive cancer and the cause of the majority of cancer-related deaths.

Quotes, details on the share and the company, notifications and historical prices

Tags: , ,

Leave a Reply

IMPORTANT! To be able to proceed, you need to solve the following simple math (so we know that you are a human) :-)

What is 3 + 13 ?
Please leave these two fields as-is:


Leave a Trackback